Tertiary lymphoid structures in lung adenocarcinoma: characteristics and related factors

Fangping Ren | Mei Xie | Jie Gao | Chongchong Wu | Yang Xu | Xuelei Zang | Xidong Ma | Hui Deng | Jialin Song | Aiben Huang | Li Pang | Jin Qian | Zhaofeng Yu | Guanglei Zhuang | Sanhong Liu | Lei Pan | Xinying Xue

1Department of Respiratory and Critical Care, Beijing Shijitan Hospital, Capital Medical University, Beijing, P.R. China
2Department of Respiratory and Critical Care, the Chinese PLA General Hospital, Beijing, P.R. China
3Department of Pathology, the Chinese PLA General Hospital, Beijing, P.R. China
4Department of Radiology, the Chinese PLA General Hospital, Beijing, P.R. China
5Center of Clinical Laboratory Medicine, the first Medical Centre, Chinese PLA General Hospital, Beijing, P.R. China
6Department of Respiratory Medicine, Weifang Medical university, Weifang, People's Republic of China
7School of Medicine, Peking University, Beijing, P.R. China
8Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China
9Shanghai Key Laboratory of Gynecologic Oncology, Renji Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai, P.R. China

Abstract

Objective: Tertiary lymphoid structures (TLSs) are found in a variety of malignancies and affect the growth of tumors, but few studies have addressed their role in lung adenocarcinoma (LAC). We aimed to evaluate clinical features associated with TLSs in patients with LAC.

Methods and Materials: A collection of resected pulmonary nodules in patients with LAC was retrospectively analyzed. TLSs were quantified by their number per square millimeter tumor area (density) and by the degree of lymphocyte aggregation (maturity) in each case. The correlation between TLS density and maturity and clinical features was calculated.

Results: A total of 243 patients were selected, of whom 219 exhibited TLSs. The occurrence of TLSs was correlated with computed tomography (CT) features as follows: pure ground-glass nodules (pGGNs) (n = 43) was associated with a lower occurrence rate than part-solid nodules (PSNs) (n = 112) and solid nodules (SNs) were (n = 88) (p = 0.037). TLS density was correlated with age and CT features. Poisson regression showed higher TLS density in PSNs and SNs than in pGGNs (incidence rate ratio [IRR]: 3.137; 95% confidence interval [CI]: 1.35–7.27;
1 | INTRODUCTION

Tertiary lymphoid structures (TLSs) are ectopic lymphoid formations with highly ordered T and B lymphocyte colonies found in nonlymphoid tissues. Similar to normal lymph nodes, TLSs provide a microenvironment for the recruitment of T cells, activation of B cells, and production of antibodies. TLSs were initially found to correlate with favorable clinical outcomes in non-small cell lung cancer (NSCLC), and in other similar malignancies, such as gastric, breast, and colorectal cancers. TLSs have been proven to improve antitumor responses and predict the efficacy of immunotherapy. The beneficial effect of TLSs on tumors positively correlates with their density and maturity in the tumor area; however, due to their remarkable heterogeneity, no effective method was found to predict TLSs.

 Although TLSs have been extensively studied in NSCLC, only a handful of studies have been carried out on their role in lung adenocarcinoma (LAC). Furthermore, those studies have mainly focused either on the function of TLS components, such as protective B cells, infiltrating T cells, and immuno-suppressive regulatory T cells, or on the possible strategies to modulate TLSs. However, whether the clinical features such as age, sex, smoking, tumor stage, or EGFR mutational status contribute to TLSs heterogeneity is largely unknown. This lack of knowledge is caused in particular by the lack of information on the relationship between TLSs and lung computed tomography (CT) features, which provide details on tumor tissue in vitro and play an important role in the management of early LAC. The answer to these questions might shed light on the heterogeneity of TLSs, as well as on their role in early LAC pathogenesis and management. Therefore, this study aimed to investigate the clinical characteristics associated with TLS in patients with LAC.

2 | MATERIALS AND METHOD

2.1 | Subjects

This study was approved by the Ethics Committee of the hospital (No. sjtyjl-2020) prior to its commencement and exempted from informed patient consent. We retrospectively analyzed a total of 3879 patients with surgically resected NSCLC from three hospitals (Qingdao University Affiliated Hospital, Chinese People’s Liberation Army General Hospital, and Beijing Shijitan Hospital Affiliated to Capital Medical University) between March 30, 2017 and May 30, 2020. Of the patients analyzed, 1838 with a postoperative pathological diagnosis of LAC were screened out, and the CT images were retrieved from the image archive and communication system (PACS). Patients who exhibited a solitary pulmonary nodule with a diameter of ≤3 cm on thin-slice chest CT were further evaluated. Patients with the following criteria were excluded: (a) no
pathological hematoxylin–eosin (HE)-stained sections available, (b) no CT images available in PACS, (c) anti-cancer therapy before surgery, (d) other uncontrolled serious diseases or mental diseases, and (e) concurrent other malignant tumors. Finally, a total of 243 patients were enrolled in this study. The inclusion flowchart is shown in Figure 1.

2.2 | CT image analysis

CT images of the whole lung were obtained using a 64-slice CT scanner with a routine scan slice thickness of 2–5 mm. The cross-sectional width of 2.0 mm and the reconstruction interval of 2.0 mm were adopted, and the thickness of the reconstructed cross-section was 1–1.5 mm. All images were reviewed at a high resolution on a 20.8 inches monitor with a 2048 × 1560-pixel gray-scale, and the window setting displayed a standard lung (window width 1500 HU, window level 600 HU) and mediastinum (window width 350 HU, window level 50 HU). The CT images were reviewed by two chest radiologists with 10 or more years’ experience to evaluate the density, size, and appearance of lung nodules. The inconsistent results were further analyzed and consensus was reached by multidisciplinary team, including two pulmonologists. Pulmonary nodules were divided into pure ground-glass nodules (pGGNs), part-solid nodules (PSNs), and solid nodules (SNs) according to CT features. Tumors were staged using the TNM staging system.24

2.3 | Pathological analysis

HE stained sections of lung nodules surgically removed from patients were evaluated by two pathologists with no less than 10 years’ experience. According to the classification for LAC jointly revised by IASLC/ATS/ERS, the nodules were divided into several types including lung adenocarcinoma in situ, minimally invasive adenocarcinoma (MIA), and lung invasive adenocarcinoma (IAC). Inconsistent analysis was clarified by consensus.

2.4 | TLSs quantification

TLSs were assessed morphologically in MIA and IAC cases using HE staining, as reported previously.25,26 TLSs were identified as (i) aggregates: clusters of lymphocytes with no distinct shape; (ii) primary follicles: lymphocyte clusters exhibiting dense, round shape with no germinal center formation, and (iii) secondary follicles: clusters of lymphocytes with germinal center formation.10 TLS
maturity was further defined as Grade I (immature TLSs): tumor with only aggregates and no follicles; Grade II (semi-mature TLSs): tumor with primary follicles with or without aggregates and without secondary follicles; and Grade III (mature TLSs): tumor with at least one secondary follicle. TLS density was quantified by the total number of TLSs identified in the tumor area, and the total number of TLSs that were in direct contact with tumor cells at the tumor edge (the number of TLSs per square millimeter tumor area).27

2.5 | Statistical analysis

General clinical features of patients, including sex, age, smoking history, EGFR gene mutation tests, CT features, and pathological types were analyzed using descriptive methods. The correlation between the above-mentioned clinical features and TLS occurrence was analyzed using binary logistic regression. The Wilcoxon rank-sum test and further Poisson regression were used to evaluate the correlation between TLS density and clinical features. The TLS maturity was analyzed using the chi-squared test and ordinal logistic regression. Statistical significance was set at \( p < 0.05 \). All data were analyzed using the STATA (version 16.0) software.

3 | RESULTS

3.1 | General clinical characteristics

In this study, 243 patients with early stage peripheral LAC, characterized by pulmonary nodules, were included. The general characteristics of the patients are summarized in Table 1. The profile of age, sex, smoking, and pathological types was in line with the characteristics of the clinical patient spectrum, except for higher frequency of EGFR mutations, as reported in the Asian population.28,29

3.2 | TLSs characteristics

A total of 219 patients were confirmed to have TLSs by pathological analysis, accounting for 90.12% of the total patients (Table 1). Among the patients with TLSs, there were 15 with typical germinal center-like structures (grade III TLSs), 58 with obvious lymphocyte clusters (grade II TLSs), and 146 with vague lymphocyte aggregation (grade I TLSs) (Figure 2). Moreover, the coexistence of different grades of TLSs and even all three grades could be found in the same tumor30 (Figure 3).

Clinical features were significantly correlated with the occurrence of TLSs as shown using the chi-square test (Table 2). Further logistic regression showed that the probability of TLSs in pGGNs was significantly lower than that in PSNs (odds ratio [OR]: 0.29; 95% confidence interval [CI]: 0.104–0.812; \( p = 0.018 \)). There was no significant difference between the PSNs and SNs.

3.3 | TLS density and maturity

The relationship between general clinical features and TLS density/maturity is summarized in Table 3. No
correlation was found between TLS density and sex, smoking, *EGFR* gene mutational status, and pathological types (*p* > 0.05), while age and CT features were found to be related to TLS density (both *p* < 0.05). Poisson regression analysis showed that TLS density was lower in patients over 60 years old than in those under 60 years old (incidence rate ratio [IRR]: 0.605; 95% CI: 0.4–0.92; *p* = 0.018). Furthermore, TLS density was significantly higher in PSNs and SNs than in pGGNs, with (IRR: 3.137; 95% CI: 1.35–7.27; *p* = 0.008) and (IRR: 2.44; 95% CI: 1.02–5.85; *p* = 0.046), respectively.

In the tests related to TLS maturity, no correlation was found with respect to age, sex, *EGFR* gene mutation, CT features, pathological types, or smoking, except for tumor stages by ordinal logistics regression. TLS maturity was higher in IB-IIIB stages than in IA1-IA3 stages (*p* = 0.026).

It is worth noting that although no correlation was found between TLS maturity and CT features, there was a tendency for less developed lymphoid structures in pGGNs (Figure 4) than in PSNs (Figure 5) and SNs (Figure 6).
In this study, we found that TLSs were ubiquitously present in LAC, with a structure of sparse lymphocytes aggregating to germinal center-like structures that resembled typical lymphoid nodes, as it was shown in other tumors.\textsuperscript{31,32} We first found that TLS occurrence was related to CT features and was lower in pGGNs than in PSNs and SNs. This result might be explained by the growth pattern of pGGNs, which consist of abnormally proliferating epithelial cells or well-differentiated tumor cells growing in a scaly manner; and since tumor cells rarely breach the

| Pathological types | TLS density (p value) | TLS maturity (Grade I II III) (p value) |
|--------------------|----------------------|---------------------------------------|
| Sex (F/M)          | 0.458 ± 0.09/0.351 ± 0.08 (0.0545) | 91–41/87/55–17–7 (0.360) |
| Age (60+/60-)      | 0.335 ± 0.05/0.528 ± 0.132 (0.0336) | 78–36–9/68–22–6 (0.508) |
| Smoking (Y/N)      | 0.442 ± 0.16/0.418 ± 0.07 (0.6179) | 19–8–6/123–50–9 (0.051) |
| EGFR mutation(Y/N)| 0.415 ± 0.06/0.434 ± 0.32 (0.0598) | 115–52–13/31–6–2 (0.218) |

TABLE 3 TLS density and maturity in different groups

$\rho < 0.05$ was considered significant.

Abbreviations: AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; IAC, invasive adenocarcinoma; pGGN, pure ground-glass nodule; PSN, part-solid nodule; SN, solid nodule.

**FIGURE 4** CT images and corresponding HE histologic findings in peripheral LAC characterized by pGGN. Top row: images in a 43-year-old man with LAC. CT manifestation is pGGN; a corresponding pathological manifestation has no obvious TLSs in tumor tissues. Bottom row: images in a 64-year-old woman with LAC. CT manifestation is pGGN, a corresponding pathological manifestation is grade I immature TLSs. CT, computed tomography; HE, hematoxylin and eosin stain; LAC, lung adenocarcinoma; pGGN, pure ground-glass nodule; TLSs, tertiary lymphoid structures.
We also found that the density of TLSs was lower in pGGNs. Although both the occurrence rate and TLS density were lower in pGGNs, this finding does not necessitate a poor prognosis as reported in other malignancies because the subjects in this study had mainly early stage tumors. In early LAC stages, tumor cells rarely break through the alveolar epithelium, and lymph node metastasis rarely develops in patients with only pGGNs. Therefore, it is doubtful that TLSs in pGGNs possess prognostic value.
When the tumor breaks through the basement membrane, the lung nodules would present more solid components and manifest as PSNs or SNs. Previous studies have suggested that the solid components in the lung nodules are caused by vascular proliferation, fibrosis, and alveolar cavity collapse, reflecting the invasive growth of LAC. In our study, it was found that the increase in the solid components in lung nodules was not only related to the increase in tumor cells, but also to the increase in the number of TLSs. However, in group comparison between PSNs and SNs, no difference was found in TLS numbers; thus, the transition from PSNs to SNs may be dominated by the increase in tumor cells and/or fiber components. These findings could help us to better understand the pathogenesis of early LAC stages.

It was also found that the number of TLSs were decreased with age, which may be related to a decline in the patient immune status. This finding might partly explain the compromised antitumor immune therapy responses in older patients.

In our study, tumor stages were found to be related to TLS maturity, which means more advanced TLS grades in higher tumor stages. This finding was in accordance with the better effect of immunotherapy observed in some higher-stage tumors. Thus, TLS profile could be a predictor of immunotherapy irrespective of tumor stage. However, further study is needed because the five different tumor stages were combined into two groups, IA1-IA3 and IB-IIB, because of the limited number of cases in the IB and IIB stages.

We also found a tendency for more advanced TLSs in PSNs and SNs compared to pGGNs. Considering the significant roles of CT features in both TLS occurrence rate and density, their roles in TLS maturity warrant further study with larger number of cases to clarify if the tendency we observed in this study really exists.

It is noteworthy that the patients enrolled in this study were limited to early stage LAC, and the results obtained may not be generalizable to all LAC stages.

## 5 | CONCLUSION

Our findings illuminate the existence of distinct profiles of TLSs in the early stages of LAC, showing their ubiquitous presence in all stages, but mainly in Grade I and Grade II. The occurrence rate and density of TLSs vary with CT features and are both lower in pGGNs, which might be explained by the growth pattern of pGGNs and thus might not necessitate a poor prognosis. The progression from pGGN to PSNs and SNs is accompanied with increased number of TLSs as well as other tumor components. Older age is also correlated with lower TLS density. TLS maturity correlates with tumor stage and might correlate with CT features. These findings provide important information on LAC tumor pathogenesis and management.

## ACKNOWLEDGMENTS

This work was supported by the National Natural Science Fund Youth Project (81700007); Research and Innovation Fund of the Ministry of Education (2018A03026); Beijing Natural Science Foundation (2019A10); “Qingmiao” plan of Beijing Municipal Hospital Administration (2018QM4); Outstanding top talent (2019YXBJ1); Capital health development scientific research unit matching fund(2020-2Z-2086); Excellent talents in Beijing “Youth top team” (2019YXBJ2); The National Natural Science Foundation of China (62176166); Beijing Hospitals Authority Clinical medicine Development of special funding support (XMLX202115); Beijing key clinical specialty project(2020ZDZK1); National major disease multidisciplinary cooperation capacity building project (2019. YLFW).

## CONFLICT OF INTEREST

The authors declare that they have no competing interest.

## ETHICAL APPROVAL

This study was approved by the Clinical Trial Ethics Committee of Beijing Shijitan Hospital (No. sjtky11-1x-2020[74]) before commencement. The requirement for written consent was waived.

## DATA AVAILABILITY STATEMENT

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

## ORCID

Sanhong Liu [https://orcid.org/0000-0001-9320-7729](https://orcid.org/0000-0001-9320-7729)

## REFERENCES

1. Dieu-Nosjean MC, Goc J, Giraldo NA, Sautès-Fridman C, Fridman WH. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 2014;35(11):571-580.
2. Stowman AM, Hickman AW, Mauldin IS, Mahmutovic A, Gru AA, Slingluff CL Jr. Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res. 2018;28(3):237-245.
3. Meng Q, Luo X, Chen J, et al. Unmasking carcinoma-associated fibroblasts: key transformation player within the tumor microenvironment. Biochim Biophys Acta Rev Cancer. 2020;1874:188443.
4. Ghosh D, Dawson MR. Microenvironment influences cancer cell mechanics from tumor growth to metastasis. Adv Exp Med Biol. 2018;1092:69-90.
5. Teillaud JL, Dieu-Nosjean MC. Tertiary lymphoid structures: an anti-tumor School for Adaptive Immune Cells and an antibody factory to fight cancer. Front Immunol. 2017;8:830.
6. Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26(27):4410-4417.
7. Li Q, Zhang D, He W, et al. CD8+ T cells located in tertiary lymphoid structures are associated with improved prognosis in patients with gastric cancer. Oncol Lett. 2020;20(3):2655-2664.
8. Sofopoulou M, Fortis SP, Vaxevanis CK, et al. The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer. Cancer Immunol Immunother. 2019;68(11):1733-1745.
9. Yamaguchi K, Ito M, Ohmura H, et al. Helper T cell-dominant tertiary lymphoid structures are associated with disease relapse of advanced colorectal cancer. Onco Targets Ther. 2020;9(1):1724763.
10. Calderaro J, Petitprez F, Becht E, et al. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. J Hepatol. 2019;70(1):58-65.
11. Cabrita R, Lauss M, Sanna A, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561-565.
12. van Dijk N, Gil-Jimenez A, Silina K, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020;26(12):1839-1844.
13. Rodriguez AB, Engelhard VH. Insights into tumor-associated tertiary lymphoid structures: novel targets for antitumor immunity and cancer immunotherapy. Cancer Immunol Res. 2020;8(11):1338-1345.
14. Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Sautès-Fridman C. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol Rev. 2016;271(1):260-275.
15. Meylan M, Petitprez F, Lacroix L, et al. Early hepatic lesions display immature tertiary lymphoid structures and show elevated expression of immune inhibitory and immunosuppressive molecules. Clin Cancer Res. 2020;26(16):4381-4389.
16. Domblides C, Rochefort J, Riffard C, et al. Tumor-associated tertiary lymphoid structures: from basic and clinical knowledge to therapeutic manipulation. Front Immunol. 2021;12:698604.
17. Pajens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021;18(4):842-859.
18. Feng H, Yang F, Qiao L, et al. Prognostic significance of gene signature of tertiary lymphoid lymphocytes in patients with lung adenocarcinoma. Front Oncol. 2021;11:693234.
19. Germain C, Gnajatic S, Tamzalit F, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med. 2014;189(7):832-844.
20. Kim A, Lee SJ, Ahn J, et al. The prognostic significance of tumor-infiltrating lymphocytes assessment with hematoxylin and eosin sections in resected primary lung adenocarcinoma. PLoS One. 2019;14(11):e0224430.
21. Joshi NS, Akama-Garren EH, Lu Y, et al. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity. 2015;43(3):579-590.
22. Tian C, Li C, Zeng Y, et al. Identification of CXCL13/CXCR5 axis’s crucial and complex effect in human lung adenocarcinoma. Int Immunopharmacol. 2021;94:107416.
23. Tang J, Ramis-Cabrè D, Curull V, et al. B cells and tertiary lymphoid structures influence survival in lung cancer patients with resectable tumors. Cancers (Basel). 2020;12(9):2644.
24. Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(4):504-535.
25. Finkin S, Yuan D, Stein I, et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol. 2015;16(12):1235-1244.
26. Ruddle NH. High endothelial venules and lymphatic vessels in tertiary lymphoid organs: characteristics, functions, and regulation. Front Immunol. 2016;7:491.
27. Helmink BA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549-555.
28. Kang L, Zheng J, Zhu X. Relationship between EGFR mutations and pathological classification and specimen of lung adenocarcinoma. Zhongguo Fei Ai Za Zhi. 2017;20(6):382-388.
29. Mi J, Wang S, Li X, Jiang G. Clinical characteristics and prognosis of sub-centimeter lung adenocarcinoma. Zhongguo Fei Ai Za Zhi. 2019;22(8):500-506.
30. Li H, Wang J, Liu H, et al. Existence of intratumoral tertiary lymphoid structures is associated with immune cells infiltration and predicts better prognosis in early-stage hepatocellular carcinoma. Aging. 2020;12(4):3451-3472.
31. Kang S, Fedoriy W, Brenneman EK, Truong YK, Kikly K, Vilen BJ. BAFF induces tertiary lymphoid structures and positions T cells within the glomeruli during lupus nephritis. J Immunol. 2017;198(7):2602-2611.
32. Bombardieri M, Lewis M, Pitizalis C. Ectopic lymphoid neogenesis in rheumatic autoimmune diseases. Nat Rev Rheumatol. 2017;13(3):141-154.
33. Aoki T, Hanamiya M, Uramoto H, Hisaoka M, Yamashita Y, Korogi Y. Adenocarcinomas with predominant ground-glass opacity: correlation of morphology and molecular biomarkers. Radiology. 2012;264(2):590-596.
34. Wang Y, Jing L, Wang G. Risk factors for lymph node metastasis and surgical methods in patients with early-stage peripheral lung adenocarcinoma presenting as ground glass opacity. J Cardiothorac Surg. 2020;15(1):121.
35. Pawelec G. Does patient age influence anti-cancer immunity. Semin Immunopathol. 2019;41(1):125-131.
36. Wu Y, Xu J, Xu J, et al. The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age. Biomark Res. 2020;8:9.
37. Lee M, Heo SH, Song IH, et al. Presence of tertiary lymphoid structures determines the level of tumor-infiltrating lymphocytes in primary breast cancer and metastasis. Mod Pathol. 2019;32(1):70-80.

How to cite this article: Ren F, Xie M, Gao J, et al. Tertiary lymphoid structures in lung adenocarcinoma: characteristics and related factors. Cancer Med. 2022;11:2969-2977. doi: 10.1002/cam4.4796